Q-omics provides the consensus-scored SOX8 profile across patient tissues and cancer cell-line models. SOX8 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, SOX8 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, SOX8 protein abundance shows 29,041 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight LGG, BLCA, and LUAD as cancer lineages where SOX8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SOX8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SOX8 survival associations across molecular data types. SOX8 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SOX8 RNA expression–survival associations across cancer types. High SOX8 expression shows unfavorable associations in ACC, MESO and UCS, but favorable associations in LGG, KICH and PAAD. The LGG Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for SOX8 RNA expression.
This table summarizes SOX8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SOX8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SOX8 shows lower tumor expression in BLCA and BRCA and higher tumor expression in THCA, KIRP, STAD and CHOL. The BLCA box plot shows higher SOX8 RNA expression in normal versus tumor tissue (log2 FC = −0.811, t-test p < 0.001).
This table shows molecular features associated with SOX8 in patient tissues and cancer cell lines. In patient samples, SOX8 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SOX8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SOFT_TISSUE.
